Movement Alert｜Guardant Health Inc. Overnight Rise 5.67%, Q2 Revenue Significantly Beats Expectations with Full-Year Guidance Raised

Market Focus07-31

On July 31, Guardant Health Inc. rose 5.67% overnight, trading at $160.99/share, with turnover of $9,622.

The movement was driven by the company's Q2 earnings release, which showed revenue of $335.0 million, up 44.3% year-over-year, significantly exceeding the consensus estimate of $314.2 million. Adjusted loss per share was $0.42, narrowing from $0.44 in the prior-year period, though slightly missing the $0.41 estimate.

Crucially, the company raised its full-year 2026 revenue guidance to $1.34 billion-$1.36 billion, up from the prior range of $1.30 billion-$1.32 billion, and well above the FactSet consensus of $1.31 billion. The strong top-line beat and raised outlook served as the primary catalysts for the overnight gain. Additionally, recent positive developments including FDA approval of Guardant360 Liquid CDx as a multi-cancer companion diagnostic, inclusion of the Shield blood test in American Cancer Society colorectal screening guidelines, and multiple analyst price target increases further supported bullish sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116822838?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 11:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116822838","market":"us","top_or_hot":-1,"title":"Movement Alert｜Guardant Health Inc. Overnight Rise 5.67%, Q2 Revenue Significantly Beats Expectations with Full-Year Guidance Raised","media":"Market Focus","content":"<p><p>On July 31, Guardant Health Inc. rose 5.67% overnight, trading at $160.99/share, with turnover of $9,622.</p><p>The movement was driven by the company's Q2 earnings release, which showed revenue of $335.0 million, up 44.3% year-over-year, significantly exceeding the consensus estimate of $314.2 million. Adjusted loss per share was $0.42, narrowing from $0.44 in the prior-year period, though slightly missing the $0.41 estimate.</p><p>Crucially, the company raised its full-year 2026 revenue guidance to $1.34 billion-$1.36 billion, up from the prior range of $1.30 billion-$1.32 billion, and well above the FactSet consensus of $1.31 billion. The strong top-line beat and raised outlook served as the primary catalysts for the overnight gain. Additionally, recent positive developments including FDA approval of Guardant360 Liquid CDx as a multi-cancer companion diagnostic, inclusion of the Shield blood test in American Cancer Society colorectal screening guidelines, and multiple analyst price target increases further supported bullish sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Guardant Health Inc. Overnight Rise 5.67%, Q2 Revenue Significantly Beats Expectations with Full-Year Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Guardant Health Inc. Overnight Rise 5.67%, Q2 Revenue Significantly Beats Expectations with Full-Year Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-31 11:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 31, Guardant Health Inc. rose 5.67% overnight, trading at $160.99/share, with turnover of $9,622.</p><p>The movement was driven by the company's Q2 earnings release, which showed revenue of $335.0 million, up 44.3% year-over-year, significantly exceeding the consensus estimate of $314.2 million. Adjusted loss per share was $0.42, narrowing from $0.44 in the prior-year period, though slightly missing the $0.41 estimate.</p><p>Crucially, the company raised its full-year 2026 revenue guidance to $1.34 billion-$1.36 billion, up from the prior range of $1.30 billion-$1.32 billion, and well above the FactSet consensus of $1.31 billion. The strong top-line beat and raised outlook served as the primary catalysts for the overnight gain. Additionally, recent positive developments including FDA approval of Guardant360 Liquid CDx as a multi-cancer companion diagnostic, inclusion of the Shield blood test in American Cancer Society colorectal screening guidelines, and multiple analyst price target increases further supported bullish sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1116822838","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116822838","pubTimestamp":1785469144,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 31, Guardant Health Inc. rose 5.67% overnight, trading at $160.99/share, with turnover of $9,622.The movement was driven by the company's Q2 earnings release, which showed revenue of $335.0...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"动态警报|Guardant Health Inc.隔夜上涨5.67%，第二季度收入大幅超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"On July 31, Guardant Health Inc. rose 5.67% overnight, trading at $160.99/share, with turnover of $9,622.The movement was driven by the company's Q2 earnings release, which showed revenue of $335.0 million, up 44.3% year-over-year, significantly exceeding the consensus estimate of $314.2 million. Adjusted loss per share was $0.42, narrowing from $0.44 in the prior-year period, though slightly missing the $0.41 estimate.Crucially, the company raised its full-year 2026 revenue guidance to $1.34 billion-$1.36 billion, up from the prior range of $1.30 billion-$1.32 billion, and well above the FactSet consensus of $1.31 billion. The strong top-line beat and raised outlook served as the primary catalysts for the overnight gain. Additionally, recent positive developments including FDA approval of Guardant360 Liquid CDx as a multi-cancer companion diagnostic, inclusion of the Shield blood test in American Cancer Society colorectal screening guidelines, and multiple analyst price target increases further supported bullish sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116822838","isCrawlerRequest":true}